Who are TP-03's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): C21, SAR408701, SM03, CHS-1420, [89Zr]Zr-crefmirlimab berdoxam, Venetoclax; Rituximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tp-03.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TP-03 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TP-03 (TP-03) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: monoclonal antibody. Area: Ophthalmology.

phase 3 monoclonal antibody CD40 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

TP-03 (TP-03) — Tarsus Pharmaceuticals, Inc.. TP-03 is a monoclonal antibody targeting the CD40 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TP-03 TARGET	TP-03	Tarsus Pharmaceuticals, Inc.	phase 3	monoclonal antibody	CD40
C21	C21	Vicore Pharma AB	phase 3	CD40 agonist	CD40
SAR408701	SAR408701	Sanofi	phase 3	Bispecific antibody; CD40/4-1BB agonist	CD40 and 4-1BB (TNFRSF9)
SM03	SM03	SinoMab BioScience Ltd	phase 3	CD40 ligand inhibitor (monoclonal antibody)	CD40L (CD154)
CHS-1420	CHS-1420	Coherus Oncology, Inc.	phase 3	Bispecific antibody	CD47 and CD40
[89Zr]Zr-crefmirlimab berdoxam	89zr-zr-crefmirlimab-berdoxam	Pfizer	marketed	Radiolabeled Monoclonal Antibody	Fibroblast Activation Protein (FAP)	Not specified
Venetoclax; Rituximab	venetoclax-rituximab	Pfizer	marketed	BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)	BCL-2 (venetoclax); CD20 (rituximab)	N/A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (monoclonal antibody class)

Pfizer · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Celltrion · 1 drug in this class
Centocor, Inc. · 1 drug in this class
Clinique des Céphalées de Montréal · 1 drug in this class
Dermira, Inc. · 1 drug in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
Gliknik Inc. · 1 drug in this class
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TP-03 — Competitive Intelligence Brief. https://druglandscape.com/ci/tp-03. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing